Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-19
1999-09-14
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514342, 514369, 514376, 5462714, 5462697, 548183, 548226, A61K 3141, A61K 3144, C07D40106
Patent
active
059523565
ABSTRACT:
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
REFERENCES:
Valiquett et al., "Troglitazone Dose-Response Study in Patients With Noninsulin Dependent Diabetes," Clinical Research, vol. 42, p. 400A (Oct. 1994).
Nolan et al., "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated With Troglitazone," The New England Journal of Medicine, vol. 331, pp. 1188-1193 (Nov. 1994).
Ciaraldi et al., "In Vitro Studies on the Action of CS-045, a New Antidiabetic Agent," Metabolism, vol. 39, pp. 1056-1062 (Oct. 1990).
Oakes et al., "A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat," Diabetes, vol. 43, pp. 1203-1210 (Oct. 1994).
Eldershaw et al., "Treatment with the Thiazolidinedione (BRL 49653) Decreases Insulin Resistance in Obese Zucker Hindlimb," Hormone and Metabolic Research, vol. 27, pp. 169-172 (Apr. 1995).
Cawthorne et al., "Anti-Hyperglycaemic Efficacy of BRL-49653, a Highly Potent Thiazolidinedione, in Animal Models of Non-Insulin Dependent Diabetes," Diabetes, vol. 42, supp. 1, abstract 654 (Jun. 1993).
Kraegen et al., "Effects of BRL 49653 in Normal and Insulin Resistant (High-Fat-Fed) Rats; New Information on the Mode of Action of Thiazolidinediones," Diabetes, vol. 42, supp. 1, abstract 257 (Jun. 1993).
Smith et al., "BRL 49653 Normalises Glycaemic Control in Zucker fa/fa Rats by Improving Hepatic and Peripheral Tissue Sensitivity to Insulin," Diabetologia, vol. 36, abstract 707 (Aug. 1993).
Young et al., "Chronic Treatment of OB/OB Mice with BRL 49653 Enhances Insulin-Stimulated Translocation of GLUT-4 to the Adipocyte Cell Surface," Diabetologia, vol. 36, abstract 285 (Aug. 1993).
Young et al., "Repeat Treatment of Obese Mice With BRL 49653, a New and Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes," Diabetes, vol. 44, pp. 1087-1092 (Sep. 1995). date.
Martindale, The Extra Pharmacopoeia, Thirtieth Edition, Edited by Reynolds, James E.F., The Pharmaceutical Press, London, pp. 276-291, 1993.
Foot, E.A. et al., "Improved Metabolic Control by Addition of Troglitazome to Glibenclamide Therapy in Non-Insulin-Dependent Diabetics", 31st Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, Sep. 12-16, 1995 (abstract only) date.
Fujita et al., "Reduction of Insulin Resistance in Obese and/or Diabetic (ADD-3878, U-63,287, Ciglitazone), a New antidiabetic Agent," Diabetes, vol. 32, pp. 804-810 (Sep. 1983).
Diani et al., "Ciglitazone, a New Hypoglycaemic Agent. 4. Effect on Pancreatic Islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db Mice," Diabetologia, vol. 27 (Aug. 1984).
Stevenson et al., "Actions of Novel Antidiabetic Agent Englitazone in Hyperglycemic Hyperinsulinemic ob/ob Mice," Diabetes, vol. 39, pp. 1218-1227 (Oct. 1990).
Adams et al., "Effects of the Antidiabetic Agent Englitazone on Hepatic Gluconeogenesis and Glycosis," FASEB Journal, vol. 9, abstract 5800 (Apr. 1995).
Clark et al., "Englitazone Sodium," Drugs of the Future, vol. 17, pp. 182-184 (Mar. 1992).
Yoshioka et al., Tonyobyou (Diabetes), vol. 34, Supplement 1 (1991) item H320 (with English translation).
Sakamoto et al., Tonyobyou (Diabetes), vol. 36, Supplement 1 (1993) item 3Q08 (with English translation).
Tanaka et al., Tonyobyou (Diabetes), vol. 37, No. 2 (1994) item 6 (with English translation).
Iwamoto et al., Tonyobyou (Diabetes), vol. 38, Supplement 1 (1995) item 2159 (with English translation).
The Pink Sheet, vol. 57, Issue 16, Re: FDC Accession No. 00570160005, Apr. 17, 1995.
Medicine and Drug Journal, vol. 30, No. 4, 1994 (Japanese) with partial English translation.
J. Sturis et al., "Prevention of Diabetes Does Not Completely Prevent Insulin Secretory Defects in the ZDF rat", vol. 269, No. 4, pp. 786-792, Oct. 1995.
Z. Bloomgarden, "American Diabetes Association Scientific Sessions, 1995", The Journal of Clinical and Applied Research and Education, vol. 18, No. 8, pp. 1215-1219, Aug. 1995.
R. Whitcomb et al., "Thiazolidinediones", Expert Opinion on Investigational Drugs, vol. 4, No. 12, pp. 1299-1309, Dec. 1995.
K. Nihalani et al., "Newer Oral Hypoglyceamic (Antidiabetic) Agents", Journal of the Diabetic Association of India, vol. 34, Nos. 3 & 4, 1994.
M. Tominaga et al. "Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats", Endocrine Journal, vol. 40, No. 3, pp. 345-349, 1993.
C. Hofmann et al., "Glucose Transport Deficiency in Diabetic Animals is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone", Endocrinology, vol. 129, No. 4, pp. 1915-1925, 1991.
J. Karam, "Type II Diabetes and Syndrome X",Endocrinology and Metabolism Clinics of North America, vol. 21, No. 2, pp. 329-350, 1992.
S. Suter et al., "Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects", Diabetes Care, vol. 15, No. 2, pp. 193-203, 1992.
T. Toyoda, Iyaku Journal, vol. 30, No. 4, pp. 1130-1134, 1994.
Y. Sugiyama et al., "Effects of Pioglitazone on Glucose and Lipid Metabolism in Wistar Fatty Rats", Arzneim.-Forsch/Drug Res., vol. 40, No. 1, pp. 263-267, 1990.
Ishida et al., "Oral Hypoglycemic Agents--New Oral Drugs and New Strategy of Treatment", Clinic All-round, vol. 43, pp. 2615-2621, 1994 (and English translation).
Therapeutic Research, 14 (No. 10), 4122 to 4126 (1993) (and English translation).
Clinic and Medicine, 9 (Suppl. 3), 19 to 37 (1993).
Clinic and Medicine, 9 (Suppl. 3), 39 to 60 (1993).
Recent Medicine, 33 197 (1982).
Sugiyama et al., "Effects of Pioglitazone on Glucose and Lipid Metabolism in Wistar Fatty Rats," Arzneim.-Forsch., vol. 40, pp. 263-267 (Mar. 1990).
Sugiyama et al., "Effects of Pioglitazone on Hepatic and Peripheral Insulin Resistance in Wistar Fatty Rats," Arzneim.-Forsch., vol. 40, pp. 436-440 (Apr. 1990).
Ikeda et al., "Effects of Pioglitazone on Glucose and Lipid Metabolism in Normal and Insulin Resistant Animals," Arzneim.-Forsch., vol. 40, pp. 156-162 (Feb. 1990).
Hofmann et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers," Diabetes Care, vol. 15, pp. 1075-1078 (Aug. 1992).
Hofmann et al., "Treatment of Insulin-Resistant Mice with the Oral Antidiabetic Agent Pioglitazone: Evaluation of Liver GLUT2 and Phosphoenolpyruvate Carboxykinase Expression," Endocrinology, vol. 130, pp. 735-740 (Feb. 1992).
Iwanishi et al., "Effect of Pioglitazone on Insulin Receptors of Skeletal Muscles From High-Fat-Fed Rats," Metabolism, vol. 42, pp. 1017-1021 (Aug. 1993).
Iwanishi et al., "New Oral Agent to Increase Insulin Sensitivity by Activating Kinase Activity of Insulin Receptors," Diabetes, vol. 39, abstract 474 (Jun. 1990).
Kobayashi et al., "Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase," Diabetes, vol. 41, pp. 476-483 (Apr. 1992).
Hofmann et al., "Insulin Sensitization in Diabetic Rat Liver by an Antihyperglycemic Agent," Metabolism, vol. 44, pp. 384-389 (Mar. 1995).
de Souza et al., "Insulin Secretory Defect in Zucker fa/fa Rats Is Improved by Ameliorating Insulin Resistance," Diabetes, vol. 44, pp. 984-991 (Aug. 1995).
Hofmann et al., "Glucose Transport Deficiency in Diabetic Animals is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone," Endocrinology, vol. 129, pp. 1915-1925 (Mar. 1991).
Colca et al., "Antihyperglycaemic Thiazolidinediones: Ciglitazone and its Analogues," New Antidiabetic Drugs, pp. 255-261 (1990).
Tominaga et al., "Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats," Endocrine Journal, vol. 40, pp. 343-349 (Jun. 1993).
Weinstock et al., "Pioglitazone: In Vitro Effects on Rat Hepatoma Cells and in vivo Liver Hypertrophy in KKA.sup.y Mice," Pharmacology, vol. 54, pp. 169-178 (Apr. 1997).
El-Kebbi et al., "Regulation of Glucose Transport by Pioglitaz
Ikeda Hitoshi
Odaka Hiroyuki
Sohda Takashi
Davis Zinna Northington
Takeda Chemical Industries Ltd.
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510115